IL283409B1 - History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them - Google Patents
History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing themInfo
- Publication number
- IL283409B1 IL283409B1 IL283409A IL28340921A IL283409B1 IL 283409 B1 IL283409 B1 IL 283409B1 IL 283409 A IL283409 A IL 283409A IL 28340921 A IL28340921 A IL 28340921A IL 283409 B1 IL283409 B1 IL 283409B1
- Authority
- IL
- Israel
- Prior art keywords
- heteroaryl
- pyrrolo
- carbonyl
- pyridine
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773620P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063510 WO2020112937A1 (en) | 2018-11-30 | 2019-11-27 | Tyk2 inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL283409A IL283409A (en) | 2021-07-29 |
| IL283409B1 true IL283409B1 (en) | 2026-03-01 |
Family
ID=70848642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283409A IL283409B1 (en) | 2018-11-30 | 2021-05-24 | History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11053241B2 (https=) |
| EP (1) | EP3886843A4 (https=) |
| JP (3) | JP7530360B2 (https=) |
| CN (1) | CN113271938A (https=) |
| AU (1) | AU2019389025B2 (https=) |
| CA (1) | CA3120866A1 (https=) |
| IL (1) | IL283409B1 (https=) |
| WO (1) | WO2020112937A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707852B (zh) | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| CA3120866A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JP2024501507A (ja) * | 2020-12-25 | 2024-01-12 | スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド | ケトヘキソキナーゼ阻害剤及びその用途 |
| CA3213816A1 (en) | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| TW202425965A (zh) * | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| CN115974751A (zh) * | 2022-12-13 | 2023-04-18 | 山东能源集团新材料有限公司 | 一种吡拉西坦制备方法及系统 |
| CN120752237A (zh) * | 2022-12-22 | 2025-10-03 | 普罗泰克特治疗有限公司 | 吡咯并吡啶和吡咯并哒嗪类化合物及其作为pkr抑制剂的用途 |
| WO2025010294A2 (en) * | 2023-07-03 | 2025-01-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and use as tyk2 inhibitors |
| US11891394B1 (en) | 2023-09-06 | 2024-02-06 | King Faisal University | Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors |
| US11878978B1 (en) | 2023-09-06 | 2024-01-23 | King Faisal University | Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors |
| US11858935B1 (en) | 2023-09-06 | 2024-01-02 | King Faisal University | Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
| CN117342955A (zh) * | 2023-10-08 | 2024-01-05 | 盐城师范学院 | 一种制备4’-甲基-联苯-2-胺的方法 |
| WO2025222103A1 (en) * | 2024-04-19 | 2025-10-23 | Raythera, Inc. | Stat6 modulators and methods of uses thereof |
| WO2025264818A1 (en) * | 2024-06-20 | 2025-12-26 | Raythera, Inc. | Stat6 modulators and methods of uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| CN1264381A (zh) * | 1997-08-05 | 2000-08-23 | 辉瑞产品公司 | 4-氨基吡咯并(3,2-d)嘧啶作为神经肽Y受体拮抗药 |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| KR20070034049A (ko) * | 2004-06-09 | 2007-03-27 | 글락소 그룹 리미티드 | 피롤로피리딘 유도체 |
| KR101764575B1 (ko) * | 2004-07-28 | 2017-08-03 | 다케다 야쿠힌 고교 가부시키가이샤 | 피롤로〔2,3-c〕피리딘 화합물, 그 제조 방법 및 용도 |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| KR102233252B1 (ko) | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | IL-12, IL-23 및/또는 IFNα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| WO2015131080A1 (en) | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| PL3137470T3 (pl) | 2014-05-01 | 2021-10-11 | Novartis Ag | Związki i kompozycje jako agonisty receptora toll-like 7 |
| EP4198031A1 (en) * | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| US10323036B2 (en) * | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| US11370794B2 (en) * | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| CA3120866A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
-
2019
- 2019-11-27 CA CA3120866A patent/CA3120866A1/en active Pending
- 2019-11-27 WO PCT/US2019/063510 patent/WO2020112937A1/en not_active Ceased
- 2019-11-27 EP EP19888308.4A patent/EP3886843A4/en active Pending
- 2019-11-27 AU AU2019389025A patent/AU2019389025B2/en active Active
- 2019-11-27 CN CN201980087661.3A patent/CN113271938A/zh active Pending
- 2019-11-27 JP JP2021530887A patent/JP7530360B2/ja active Active
- 2019-11-27 US US16/697,371 patent/US11053241B2/en active Active
-
2021
- 2021-05-14 US US17/320,394 patent/US11834449B2/en active Active
- 2021-05-24 IL IL283409A patent/IL283409B1/en unknown
-
2024
- 2024-07-26 JP JP2024120957A patent/JP2024160253A/ja active Pending
-
2025
- 2025-12-26 JP JP2025283785A patent/JP2026053668A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026053668A (ja) | 2026-03-25 |
| JP2022509260A (ja) | 2022-01-20 |
| AU2019389025A1 (en) | 2021-06-17 |
| JP7530360B2 (ja) | 2024-08-07 |
| US11053241B2 (en) | 2021-07-06 |
| WO2020112937A1 (en) | 2020-06-04 |
| IL283409A (en) | 2021-07-29 |
| AU2019389025B2 (en) | 2025-07-24 |
| EP3886843A4 (en) | 2022-08-31 |
| US20200172540A1 (en) | 2020-06-04 |
| JP2024160253A (ja) | 2024-11-13 |
| US11834449B2 (en) | 2023-12-05 |
| CN113271938A (zh) | 2021-08-17 |
| US20220106306A1 (en) | 2022-04-07 |
| EP3886843A1 (en) | 2021-10-06 |
| CA3120866A1 (en) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283409B1 (en) | History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them | |
| EP4072593A4 (en) | BIOACTIVABLE CYTOKINE DRUGS AND ASSOCIATED METHODS OF USES | |
| AU2022221446A1 (en) | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | |
| IL286471B1 (en) | The history of phenylisoxazolidine (pyridine-amino-phenyl)-acrylamide, a method for their preparation and a pharmaceutical preparation containing them | |
| PH12015502792A1 (en) | Crystalline bromodomain inhibitors | |
| IL281924A (en) | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | |
| IL285008A (en) | Methods for the production and use of myceliated amino acid-supplemented food compositions | |
| ZA202202932B (en) | Fxia inhibitors and preparation method therefor and pharmaceutical use thereof | |
| EP3250572A4 (en) | Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | |
| SG11202111701XA (en) | Coated drug compositions and methods of preparing the same | |
| IL252578B (en) | History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them | |
| MX2021014674A (es) | Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas. | |
| EP3312175A4 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| SG11201400092VA (en) | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them | |
| SG11202107848TA (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| IL311733A (en) | Hydrochloride salt of inupdanant, pharmaceutical preparations and methods of using it | |
| IL280376A (en) | The history of boronic acid, its preparation and pharmaceutical preparations containing it | |
| SI3746441T1 (sl) | Farmacevtska spojina, njene soli, njene formulacije ter postopki izdelave in uporabe le-teh | |
| EP3898582A4 (en) | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF | |
| EP3248981A4 (en) | C14-hydroxyl esterified amino acid derivatives of triptolide, and preparation method and use thereof | |
| EP3813842A4 (en) | PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF | |
| IL288542A (en) | Methods and compositions for microbial delivery of double stranded rna | |
| IL286416A (en) | Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration | |
| EP3915986A4 (en) | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THEM AS ACTIVE PRINCIPLE |